Introduction: The genetic architecture of Alzheimer's disease (AD) is only partially understood. Methods: We conducted an association study for AD using whole sequence data from 507 genetically enriched AD cases (i.e., cases having close relatives affected by AD) and 4917 cognitively healthy controls of European ancestry (EA) and 172 enriched cases and 179 controls of Caribbean Hispanic ancestry. Confirmation of top findings from stage 1 was sought in two family-based genome-wide association study data sets and in a whole genome-sequencing data set comprising members from 42 EA and 115 Caribbean Hispanic families. Results: We identified associations in EAs with variants in 12 novel loci. The most robust finding is a rare CASP7 missense variant (rs116437863; P 5 2.44 ! 10
Introduction
Late-onset Alzheimer's disease (AD) is a progressive neurodegenerative disorder in persons aged 65 years and older which is characterized by memory loss and dementia.
AD risk increases exponentially with age with a prevalence of 30-40% among persons aged 85-89 years [1] . As average life expectancy has increased, the number of AD cases will increase to 11-16 million by 2050, with nearly 1 million new cases per year unless measures are identified to delay or prevent the disease [2, 3] .
Risk of AD is modulated by variants in multiple genes, most notably the APOE 32 and 34 alleles, in combination with lifestyle and environmental factors. AD has a substantial genetic component with an estimated heritability of 58-79% [4] . Genome-wide association studies (GWAS) have identified .20 common susceptibility variant loci showing robust evidence for the association with AD [5] [6] [7] . Recently, studies that performed whole exome sequencing (WES), targeting gene sequencing and rapid throughput genotyping using single nucleotide polymorphism microarray chips with high exome content, have reported associations with rare risk variants in multiple novel loci including TREM2 [8] [9] [10] , PLD3 [11] , AKAP9 [12] , UNC5C [13] , PLCG2 [14] , and ABI3 [14] , as well as with rare risk and protective variants in several previously known AD genes (APP [15, 16] , APOE (p.V236E) [17] , SORL1 [18] , and ABCA7 [19, 20] ). The Alzheimer's Disease Sequencing Project (ADSP) is an National Institute of Health-funded initiative to identify novel genes and rare risk and protective variants using WES and whole genome sequencing (WGS) approaches. In this study, we analyzed a subset of the ADSP WES cohort including "enriched" AD cases (i.e., cases who have close relatives also affected by AD and thus more likely to have a high burden of AD risk alleles than cases not ascertained on the basis of a positive family history) and all controls to identify novel associations with single-nucleotide variants (SNVs) and short insertions and deletions (indels).
Methods

Participants, sequencing, and data processing
The ADSP performed WES of DNA specimens from 5778 AD cases and 5136 controls at three National Human Genome Research Institute Genome Centers (Broad Institute at Baylor College of Medicine and McDonnell Genome Institute at the Washington University). Detailed description of the ADSP WES study design has been published elsewhere [21] . In brief, subjects for this study were selected from data sets assembled by the Alzheimer's Disease Genetics Consortium (ADGC), Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, and the Rotterdam Study [5, 22] . In the ADSP WES European ancestry (EA) cohort, w5000 AD cases that were not ascertained on the basis of family history of AD were selected because they have the lowest risk explained by age and APOE genotypes (young onset, APOE 32/ 32, 32/ 33, or 33/ 33) . Approximately 5000 cognitively normal controls were selected as controls least likely to convert to a case based on age, APOE, and autopsy data (old; APOE 32/ 32, 32/ 33, or 33/ 33; and little or no AD neuropathology). In addition, w700 unrelated cases were selected from additional multiplex families with .2 close relatives affected by AD in each family, but only one case was selected from each family (i.e., "enriched cases"). To enhance discovery of novel ADrelated variants, enriched cases that could be explained by cosegregation of APOE 34 were excluded.
After performing a series of filtering steps to identify duplicate samples and subjects with low genotype call rates, there remained a sample containing 10,441 individuals of EA and 395 Caribbean Hispanics (CHs). Subjects for this study included 679 unrelated AD cases (507 EA and 172 CH) from families containing at least three members affected by AD and 5094 unrelated controls (4917 EA and 177 CH). Characteristics of the 5773 subjects included in this study are shown in Supplementary Table 1 . Compared with the overall ADSP case-control study design, EAenriched cases are older (age at onset 5 83.6 years) and similar in age to the controls (age at last examination 5 86.5 years). The mean age at onset of CHenriched cases (75.4 years) is similar to the mean age at last examination (73.5 years) of the CH controls.
WES and quality control
Details of variant calling pipelines are described in Supplementary Methods. After sequencing, 100-bp pairedend reads were mapped to human reference genome (GRCh37/hg19) using the Burrows-Wheeler Aligner [23] . The ADSP quality control (QC) working group applied QC protocols to autosomal biallelic SNVs and short insertions and deletions (indels) to generate a high-quality variant call set. After QC, there remained 1,454,483 SNVs and 69,931 indels for association analyses.
Single-variant association analyses
In stage 1, the association of AD with each variant having a minor allele count (MAC) of 10 (100,338 variants for EA and 64,691 for CH; Fig. 1 and Supplementary Table 2) was tested in each population using score tests in seqMeta (https://github.com/DavisBrian/seqMeta) with three additive logistic regression models. A MAC cutoff of 10 is the minimum number of alleles to achieve statistical significance in this sample. A minimal adjustment model (model 0) included covariates for sequencing center and principal components (PCs) of ancestry (the first 10 PCs for EAs and the first 3 PCs for CHs) to identify variants whose effects on AD risk are confounded by age and sex. This model was previously shown to increase the efficiency of detection of associations in this sample in which the mean age is substantially different between cases and controls [24] . A second model (model 1) also included terms for age and sex, and a third model (model 2) included all covariates from model 2 plus terms for the number of APOE 34 and 32 alleles. Results from analyses of 46,425 variants that were successfully called and passed criteria for single-variant analysis in the EA and CH data sets were combined using an inverse variance-weighted meta-analysis approach implemented in seqMeta after applying genomic control. A Bonferroni correction was applied to define study-wide significance (SWS) in each group (EA: P , 4.98 ! 10
27
, CH: P , 7.73 ! 10
, and meta P , 1.08 ! 10
26
; Supplementary Table 2 ).
It is well-known that the standard maximum likelihood estimation of the logistic model can suffer from smallsample bias [25] . We applied a penalized likelihood method (i.e., the Firth logistic regression test [25] [26] [27] ) to evaluate the association of the odds ratio (OR) and confidence intervals for all top single variants using Heinze's "logistf" package in R (http://cemsiis.meduniwien.ac.at/en/kb/science-research/ software/statistical-software/fllogistf/).
Gene-based association analysis
In an attempt to improve power by removing nonfunctional variants, we selected variants on the basis of annotated function using the Ensembl Variant Effect Predictor [28] and SnpEff [29] software as follows: (1) high impact: variants classified as splice acceptor, splice donor, stop gained, frameshift, stop lost, start lost, or transcript amplification; (2) high or moderate impact: included the categories mentioned previously plus variants annotated as in-frame insertion, in-frame deletion, missense variant, or protein altering. Association was tested for genes with 2 variants and a cumulative MAC 10 after excluding variants with a minor allele frequency (MAF) 0.05 using the same three models tested in the individual variant analyses and the SKAT-O program in seqMeta [30] . Separate analyses were performed for high-impact variants only (2298 genes in EAs and 314 genes in CHs) and for high-and moderateimpact variants (16,026 genes in EAs and 11,743 genes in CHs). Analyses of the combined populations included 1941 genes with high-impact variants and 14,960 genes with high-or moderate-impact variants. The ethnicspecific gene-based results were combined by metaanalysis of Z-scores weighted by the number of subjects using seqMeta, assuming the same direction of effect on a gene in both populations. Significance thresholds for each analysis were determined based on the number of genes tested (Supplementary Table 3 ).
Stage 2 analyses in GWAS data sets
We attempted to confirm the top-ranked discovery-stage results from single-variant analysis (P , 1.0 ! 10 25 ) and gene-based tests (P , 1.0 ! 10 24 ) obtained from the best-model (i.e., the smallest P value among the three models tested for each individual variant or gene) using ADGC GWAS data sets, in which genotypes for w39M variants as rare as MAF 5 0.0004 were imputed with the Haplotype Reference Consortium (HRC) r1.1 reference panel [31] using MiniMac3 (see Supplementary Methods for additional details of imputation procedures). To be consistent with the enriched case design of the discovery analyses, we evaluated the two ADGC family-based cohorts, Multiinstitutional Research in Alzheimer's Genetic Epidemiology Study (449 AD cases and 704 controls) and National Institute on Aging Late Onset Alzheimer's Disease Family Study (1568 cases and 1457 controls), after excluding subjects who were included in the ADSP WES data set (Table 1) . Models 1 and 2 only were evaluated in each data set using imputed allele dosages for each variant, generalized estimating equations implemented in geepack R package for single-variant tests, and "F-SKAT" [32] for gene-based tests to account for the family structure. Model 0 was not evaluated in stage 2 data sets because these samples did not have unique ascertainment schemes for AD cases and controls on the basis of age and sex. Results from the stage 2 data sets were combined using a fixed-effects inverse variance-weighted method in METAL [33] applied to single-variant results and the sample size-weighted Z-score method applied to gene-based results. Successful replication was determined using a nominal significance threshold (P ,.05), and for single variants, if the effect direction was the same as that in the stage 1 and 2 data sets. Results from stages 1 and 2 were combined using the same meta-analysis approach. Results for models 0 and 1 in the stage 1 data set were each metaanalyzed with those obtained from model 1 in the stage 2 data sets.
Stage 2 analyses in the ADSP family-based WGS data set
We further examined the top-ranked discovery-stage results (52 individual variants and eight genes) in the ADSP WGS family-based data set [21, 34] . This data set includes 197 individuals sequenced in 42 EA families and 501 individuals in 115 CH families. Association of individual variants was evaluated by inspecting their segregation within families. Gene-based tests were conducted separately for EA and CH families using F-SKAT.
Results
There was little evidence for genomic inflation in single variant-based exome-wide results in the EA (l 5 0.92), CH (l 5 1.05), or combined populations (l 5 1.07; Supplementary Fig. 1 ).
Single-variant results in EAs
In model 0, rare variants in TREM2 (P 5 4.56 ! 10 212 ), NPC1 (P 5 5.78 ! 10 29 ), CASP7 (P 5 2.44 ! 10 210 ), and KCNK13 (P 5 1.55 ! 10 27 ) were significantly associated with AD (Table 2 ; Supplementary Fig. 2 ). After adjusting for age and sex (model 1), the evidence for association with all four genes was reduced, but the TREM2 and NPC1 variants were still significant (P , 5.0 ! 10 27 ). Additional adjustment for APOE genotype (model 2) further diminished associations with all genes but NPC1 (P , 9.41 ! 10 25 ; Supplementary Table 4 ). In addition to the previously known TREM2 R47H variant [8] [9] [10] , 52 variants including two indels from 50 novel loci met criteria for follow-up in the stage 2 data sets. Analyses of these variants yielded nominally significant (P , .05) results; however, only the CASP7 variant showed the same effect direction, and this association was slightly more significant (P 5 1.92 ! 10 210 ) in the combined stage 1 1 2 sample (Table 2; Supplementary Table 5 ). This CASP7 variant is a previously identified missense mutation (rs116437863) that results in an amino acid substitution of glycine for arginine and is predicted to be deleterious and probably damaging by SIFT [35] (score 5 0) and PolyPhen [36] (score 5 0.99).
Single-variant results in CHs
No variants reached SWS (P , 7.73 ! 10 27 ) in the CH group. However, notable novel association signals were observed with an SNV in LDB3 (P 5 5.11 ! 10 26 ), a previously known 6-bp frameshift deletion (rs782084513) in ORAI1 (P 5 5.34 ! 10 25 ) and a 3-bp deletion in KLHL40 (P 5 7.98 ! 10 25 ). The strength of these associations was similar in all three models (Supplementary Table 6 ), indicating that they are independent of age, sex, Table 7 ). However, a rare variant SLAIN1 showed mild evidence of association in both EA (P 5 .00015) and CH (P 5 .0023) groups, and the model 0 result from the two groups combined approached SWS (meta P 5 4.68 ! 10 26 ; Supplementary Table 8 ).
Gene-based association results
In analyses focused on high-impact variants, associations with six novel loci were SWS (P , 2.18 ! 10 25 ), including JMJD4, C1orf173, ANXA5, AARD, ASCC1, and ASB13 (Table 3) . Results for two additional novel genes (DTYMK and IGHJ6) were SWS (P , 3.12 ! 10 26 ) in analyses that included high-and moderate-impact variants. Among these findings, only AARD showed evidence for association in the stage 2 data sets (P 5 6.16 ! 10 23 ). However, associations were strengthened for C1orf173 (P 5 1.50 ! 10 25 ), ANXA5 (P 5 2.27 ! 10 25 ), and AARD (P 5 1.01 ! 10 26 ) in the combined stage 1 1 2 data set. Although none of the gene-based tests were SWS in the CH group, analyses of high-and moderate-impact variants revealed a significant association with KLHL40 (P 5 9.98 ! 10 25 in model 0 and P 5 1.01 ! 10 24 in models 1 and 2). Table 4 ) and eight genes (Table 3) were further examined in the ADSP WGS family-based data set. Low-frequency missense variants in AIM1L (rs80177817, MAF 5 0.02, discovery P 5 6.14 ! 10 27 ) were observed and segregated nearly perfectly with the disease in two EA families and one CH family. A previously identified rare frameshift mutation in DHX37 (rs779974893, MAF 5 0.001, stage 1 P 5 7.68 ! 10 26 ) and the known AD-associated rare missense mutation in TREM2 (R47H, MAF 5 0.003) each occurred and segregated with disease in one EA family (Supplementary Table 9 26 ) each showed a high degree of cosegregation with the disease in two CH families. None of the genebased tests in EA or CH families were nominally significant (P . .20; Supplementary Table 10 ), noting that none of the rare variants that primarily accounted for the gene associations in the stage 1 sample were observed in the WGS families (Supplementary Table 11 ).
Stage 2 results in the ADSP family-based WGS data
SWS and suggestive associations for 52 individual variants (Supplementary
Findings for previously reported AD-associated rare variants
Of 15 rare variants previously reported to be associated with AD, two non-exonic ABCA7 variants were not included in the WES capture. Three of the tested seven variants (i.e., those with MAC 10) were significantly associated with AD after correcting for the number of tests (P , .007) in a model adjusting for age, sex, and APOE dosage: (1) PLD3-V232 M, (2) ABI3-S209 F, and (3) SORL1-A528 T (Supplementary Table 12 ).
Discussion
We identified novel associations for AD with a single rare variant in CASP7 and gene-based tests of aggregated rare variants in C1orf173, ANXA5, and AARD in 5094 controls and a subset of 679 unrelated familial AD cases from the ADSP. These findings were study-wide significant and improved when combined with results obtained from HRC-imputed data from 2161 AD cases and 2017 controls in two family-based ADGC GWAS data sets. Study-wide significant findings at the variant or gene level were observed for several other loci (NPC1, KCNK13, HOXB2, HTR3A, ZNF333, STAB1, SCN4A, MUC17, AKNAD1, KANSL3, TMEM87A, OTOG, DTYMK, and IGHJ6), but these findings were not bolstered by the stage 2 data sets. A previous study by the ADSP of the entire WES data set including 5740 AD cases reported associations with one rare variant in AC099552.4 and nine high-impact aggregated variants in ZNF655 [35] . The greatly improved detection of associations with rare variants in this smaller sample of AD cases is likely due to the enriched case design. For example, the result for the established rare TREM2 R47H variant (P 5 4.56 ! 10 212 ) is virtually identical to the result for this variant in the prior study [35] , which is consistent with the observation of the R47H variant only among enriched AD cases in the entire data set. None of the other top association findings in this study were remarkable in the analysis of the enlarged ADSP sample, including cases that were not ascertained on the basis of family history of AD; the strongest signals were observed for KCNK13 (P 5 .0063) and HOXB2 (P 5 .0019) (Supplementary Table 13 ).
CASP7 encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution phase of cell apoptosis. Caspase-7 is a protease involved in apoptosis and inflammation [37] . Activation of caspase apoptotic pathways involves apoptosome assembly [38] , and multiple recent studies link this process to aging and AD neuropathology, including caspase cleavage of amyloid precursor protein [39] [40] [41] and tau [40, 42] (Fig. 2) . Roles for other caspases in AD pathogenesis have been described, including caspase-6 in cognitive impairment [44] and tau cleavage [45] ; caspase-8 in amyloid processing, synaptic plasticity, learning, memory, and control of microglia proinflammatory activation and associated neurotoxicity [46, 47] ; and caspase-9 activation in tau cleavage [48] . Su et al. reported that activated caspase-3 expression correlates with Alzheimer pathology [49] . Caspase-3 is processed by caspases 8, 9, and 10 and is the predominant caspase involved in the cleavage of amyloid precursor . C31 is one of several C-terminal fragments produced from APP, and there is some evidence that it is toxic [43] .
protein, which is associated with neuronal death and plaque formation in AD brain [50] . A recent targeted sequencing study of genes involved in amyloid metabolism found an association of AD with two CASP8 rare variants [47] . Our finding of a rare missense variant in CASP7 provides additional evidence for the role of caspase apoptotic pathways in AD. Further functional studies of CASP7, and the rs116437863 missense variant in particular, are needed to define its role in AD pathogenesis and evaluate the potential of caspase-7 inhibition as an AD treatment strategy.
The association with a rare 3-bp in-frame deletion (rs550307753) in TMEM87A reached the SWS in EAs (P 5 2.79 ! 10 27 ), but this finding could not be replicated because this variant was not genotyped or imputed well in the ADGC GWAS data sets.
Gene-based tests considering only highly deleterious SNVs and indels yielded highly significant associations with three novel genes (C1orf173, ANXA5, and AARD) which were strengthened by meta-analysis with results from the stage 2 data sets. ANXA5 is phospholipase A2 kinase C inhibitory protein that has been implicated in membrane-related events along exocytotic and endocytotic pathways and in AD [51] . The function of Corf173 (alias ERICH3-glutamate rich 3) is largely unknown. AARD has no obvious connection to AD or brain. IGHJ6 was another SWS gene-based finding that did not replicate because none of the high-or moderate-impact rare variants each occurring only once or twice in the stage 1 sample were observed in the stage 2 data sets. This gene encodes one of the immunoglobulin heavy gamma variable chains and is a very good candidate given its functional similarity to IGHG3, one of the top associations in the entire ADSP WES sample [52] , and evidence that antibodies to IgG cross-react with fibril and oligomer amyloid-b aggregates [53] .
In comparison with the EA cohort, the CH cohort is very small with only 172 enriched cases and 177 controls. Nonetheless, we observed suggestive CH-specific association signals with three infrequent (2% ,MAF , 5%) previously known variants including an SNV (rs76615432) in LDB3 (P 5 5.11 ! 10 26 ), a small deletion causing a frameshift (rs782084513) in ORAI1 (P 5 5.34 ! 10 25 ), and a small deletion in KLHL40 (P 5 7.98 ! 10 25 ). Notably, KLHL40 is the only gene which yielded top-ranked results from individual variant and gene-based tests, largely due to the fact that among nine distinct KLH40 variants that were observed, one SWS variant (rs34020089) accounted for 21 of the 36 aggregated rare variants (i.e., MAC 5 36) in the gene-based test (Supplementary Table 6 and  Supplementary Table 14) .
Several strengths and limitations of our study warrant discussion. One of the major strengths lies in the careful clinical and genetic characterization of all individuals enrolled in the ADSP. Another strength of the study is the enriched case design which strengthened the genetic signals, thus allowing detection of associations that would otherwise be missed in a larger traditional case-control study.
A major limitation of the study is that the sample sizes are relatively small especially for enriched AD cases and the CH group overall. In the stage 1 EA group, the enriched cases represent approximately 10% of the total sample which had sufficient power to detect association with moderateeffect variants [24] . It has been shown that one can reduce the sample size of cases approximately four-fold using cases who have at least two affected relatives to have the same power as a sample of cases that are not ascertained on the basis of family history [54] . Although our case sample was not large enough to benefit fully from the enriched cases design, it was sufficient to detect association with highly penetrant variants whose effects would be diluted in a sample not ascertained on the basis of family history [54] . This idea is exemplified by the TREM2 R47H variant for which we observed similar P values but a higher OR in the present study (P 5 4.56 ! 10 212 , OR 5 11.82; Supplementary Table 13) than the finding for this variant in the total group of ADSP cases (P 5 4.8 ! 10
212 , OR 5 3.61) [35] . Another limitation is that coding variants were identified directly in the stage 1 data set but imputed in the stage 2 GWAS data sets with varying degrees of confidence for those with MAF , 0.5%-1.0%. To be consistent with the study design of the discovery-stage analysis, we included only family-based cohorts from the ADGC HRC-imputed GWAS data set, Multiinstitutional Research in Alzheimer's Genetic Epidemiology Study, and National Institute on Aging Late Onset Alzheimer's Disease Family Study, in stage 2, and thus had little power to confirm our findings. The relatively small size and unreliable imputation of very rare variants in the stage 2 sample particularly limited our ability to replicate findings from gene-based tests. Also, the ADSP WES study design, for which AD cases were selected to have relatively early onset and a lower frequency of the APOE ε4 allele and controls were selected to be as old as possible with preference given to those having at least one APOE ε4 allele to enrich this group for protective variants, introduced confounding between age and AD status which reduced the power for detecting associations. To overcome this limitation, we included a model without age adjustment. These limitations underscore the need to replicate our findings in other data sets containing enriched cases. Finally, our primary analysis relied on the score test which is prone to increased type I errors for rare variants in unbalanced samples [55] . For this reason, we re-evaluated our top results using the Firth test. This analysis showed that the finding of the rare CASP7 variant is attenuated (P 5 2.21 ! 10 25 ). Recognizing that the Firth test overcorrects for bias in very sparse data [24] , the true P value may be between those obtained using the score and Firth tests.
In summary, we identified multiple novel associations for AD with individual and aggregated rare variants using an enriched case-control study design. A better understanding of the molecular mechanisms underlying these associations will require functional experiments and in silico studies of the connections of genetic variants to gene expression and processing of AD-related proteins.
